Literature DB >> 3786258

Nuclear protein matrix as a target for estramustine-induced cell death.

B Hartley-Asp, E Kruse.   

Abstract

The effect of estramustine [estradiol 3-N-bis(2-chloroethyl)carbamate] on the human prostatic tumor cell line 1013L was investigated. Cell proliferation experiments revealed that estramustine cytotoxicity varied during the different phases of cell growth. Maximum cell killing was found in early log phase, but cell death also occurred in the stationary phase. Mitotic arrest was found at cytotoxic concentrations throughout the log phase. Subcellular distribution studies showed that the cellular uptake of estramustine increased throughout the log phase and remained steady during the stationary phase. Nuclear uptake in contrast was similar in all phases, whereas a preferential binding to the nuclear protein matrix was found to increase throughout the log phase and even during the stationary phase of growth. This implicates the nuclear protein matrix as a target for estramustine cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3786258     DOI: 10.1002/pros.2990090408

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  9 in total

1.  Presence of oestrogen receptors on target cells and antiproliferative activity of estramustine phosphate: positive correlation for human tumours in vitro.

Authors:  J Pavelić; I Zgradić; K Pavelić
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II), a new drug not only parenterally but also orally active in the therapy of breast and prostate cancer.

Authors:  T Spruss; S Schertl; M R Schneider; R Gust; K Bauer; H Schönenberger
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 3.  Oral chemotherapy in the treatment of hormone-refractory prostate cancer.

Authors:  K J Pienta; J M Kamradt; D C Smith
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 4.  Pharmacokinetics and pharmacodynamics of estramustine phosphate.

Authors:  A T Bergenheim; R Henriksson
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

Review 5.  Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.

Authors:  C M Perry; D McTavish
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923

6.  The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer.

Authors:  Mario A Eisenberger; Emmanuel S Antonarakis
Journal:  Urol Clin North Am       Date:  2012-11       Impact factor: 2.241

7.  Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype.

Authors:  L A Speicher; V R Sheridan; A K Godwin; K D Tew
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

Review 8.  Recent advances in chemotherapy for advanced prostate cancer.

Authors:  K B Olson; K J Pienta
Journal:  Curr Urol Rep       Date:  2000-05       Impact factor: 2.862

9.  DNA fragmentation induced by the antimitotic drug estramustine in malignant rat glioma but not in normal brain--suggesting an apoptotic cell death.

Authors:  C Vallbo; T Bergenheim; A Bergh; K Grankvist; R Henriksson
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.